| FRIDAY, APRIL 25, 2003 |
| |
|
| Infertility and ART |
Hall A
|
|
| 08:30 – 10:00 |
CLONING AND STEM CELLS |
| Co-Chair: |
J. Cohen, France
R. Felberbaum, Germany
D. Baird, UK |
| Capsule: |
Are we stepping into the dark? Can we differentiate
between the risks and the benefits? |
| |
- Nuclear and cytoplasmic transfer - what are the risks?
Y. Ménézo, France
- Human Umbilical Cord Blood Stem Cells: Can They Replace Embryonic
Stem Cells?
R.F. Casper, Canada
- Embryonic steps towards stem cell medicine
R.A. Pedersen, UK
- Cloning of human beings - should we ban it?
R. Felberbaum, Germany
|
| 10:30 – 12:00 |
CLINICAL ASPECTS OF OVARIAN STIMULATION |
| Co-Chair: |
L. Mettler, Germany
C. Chillik, Argentina
H.J. Out, The Netherlands |
| Capsule: |
The debate still continues, searching for optimal
methods |
|
- Is LH needed for optimal ovulation induction?
J. Balasch, Spain
- Donor Eggs: Charity or Trade?
K. Ahuja, UK
- Induction of ovulation and ovarian cancer - Is there an association?
L. Lerner-Geva, Israel
- Does environmental pollution affect human reproduction?
R.F. Casper, Canada
|
| 12:30 - 14:30 |
FEMALE HEALTH CARE IN THE CLIMACTERIC: IS HORMONE
THERAPY STILL AN OPTION? |
|
Luncheon Session - Industrial Session
Sponsored by Schering AG |
| Co-Chair: |
J. Stevenson, UK |
| |
- Introduction
J. Stevenson, UK
- Use of hormone therapy in Europe
H.P.G. Schneider, Germany
- The biological rationale for estrogen therapy
M. Notelovitz, USA
- The role of different progestins beyond endometrial protection
M. Gambacciani, Italy
- Hormonal therapy and cancer risks
M. Espié, France
- The cardiovascular issue
P. Collins, UK
- Conclusions and results of voting
J. Stevenson, UK
|
| 15:15– 16:45 |
MINIMAL WORKUP BEFORE INFERTILITY TREATMENT |
| Co-Chair: |
V. Insler, Israel
P.N. Barri, Spain |
| Capsule: |
Can we do without all the expensive sophisticated
tests? |
| 15:15 |
Diagnostic laparoscopy ever indicated?
N. Laufer, Israel
|
| 15:33 |
Sophisticated sperm analysis ever required?
F. Comhaire, Belgium |
| 15:51 |
Salpingoscopy, Microsalpingoscopy, HSG.
Do we need them all?
H.C. Verhoeven, Germany |
| 16:09 |
Basal hormonal profile any value? What's
the evidence?
M.P. Brincat, Malta |
| 16:27 |
Summary and Conclusion
V. Insler, Israel |
| 16:45-18:45 |
MALE INFERTILITY |
| Co-Chair: |
B. Lunenfeld, Israel
M. Tobler, Germany
R.F. Casper, Canada |
| Capsule: |
Can all problems be overcome with ICSI? |
 |
- Hormones, antioxidants and food supplementation in the treatment
of infertile male: benefit to the patient or to the industry?
F. Comhaire, Belgium
- Should we treat Kleinfelter Syndrome patients with IVF-ET?
J. Levron, Israel
- Round and elongated spermatides injection: Should it be used?
S. Al-Hasani, Germany
- Gender selection for non genetic reasons
J. Schenker, Israel
|
| Gynecology / Menopause and Family
Planning |
Hall B
|
|
| 08:30 – 10:00 |
FAMILY PLANNING
Endorsed by the Tarnesby chair of fertility regulation |
| Co-Chair: |
S.O. Skouby, Denmark
A. Volpe, Italy |
| Capsule: |
What are the advantages of the new methods of family
planning? |
| 08:30 |
OC’s OTC?
G. Creatsas, Greece
|
| 08:52 |
OC’s until HRT? To whom?
A. Evans, UK |
| 09:14 |
Do third generation OC’s increase thrombosis risk?
J. Cohen, France |
| 09:36 |
The Levonorgestrel IUS: More Than Just Contraception?
A. Evans, UK |
| 10:30 - 12:15 |
NEW ADVANCES IN ACNE TREATMENT WITH OCs: SHOULD
20 mcg EE BE FIRST-LINE THERAPY?
Industrial Session
Sponsored by Wyeth Pharmaceuticals |
| Co-Chair: |
S.O. Skouby, Denmark
J. DiGiovanna, USA |
| 10:30-10:40 |
Welcome and Introductions What are the advantages
of 20 mg EE OCs?
S.O. Skouby, Denmark |
| 10:40-11:00 |
The Pathophysiology of Acne
J. DiGiovanna |
| 11:00-11:25 |
Are OCs Effective Treatment for Acne? A Clinical Update
and Review of the Literature
J. Huber |
| 11:25-11:40 |
Do Antibiotics Affect OCs Performance?
S.O. Skouby, Denmark |
| 11:40-12:00 |
How Can We Improve Patient Satisfaction and Compliance
With OCs?
C. Lynch |
| 12:10-12:15 |
Panel Discussion/Q&A |
| |
|
| 15:15– 16:45 |
TREATMENT OF MENOPAUSE |
| Co-Chair: |
S. Rozenberg, Belgium
P.E. Schwartz, USA
E. Peer, Israel |
| Capsule: |
Basic aspects of treatment remain controversial |
| 15:15 |
Hysterectomy is the most common major Gynecological procedure
and yet we still don't know what to do with the adnexae Normally
functioning ovaries should be left during hysterectomy
Pros L.P. Shulman, USA
Cons J. Studd, UK
|
| 16:00 |
Women are usually given estrogen doses,
which are too high
Yes: J. Stevenson, UK
No: J. Studd, UK |
| 16:45– 18:45 |
OVARIAN AND BREAST CANCER: SCREENING AND PROPHYLACTIC |
| Co-Chair: |
W. Jonat, Germany
P.E. Schwartz, USA
U. Beller, Israel |
| Capsule: |
Recent confusion began over the benefits of mammography
screening in detecting cancer before a lump is detectable during physical
examination. Should annual mammograms be routine for women over 40? |
|
- Do routine mammograms save lives? Why are there different recommendations
if the data is similar?
I. Schreer, Germany
- Surgical options for breast cancer
W. Jonat, Germany
- Prophylactic mastectomy
M. Kiechle, Germany
- Prophylactic oophorectomy in BRCA carriers with or without hysterectomy
P.E. Schwart, USA
|
| Perinatology and Prenatal Diagnosis |
Hall C
|
|
| 08:30-10:00 |
MID-TRIMESTER MISCARRIAGE |
| Co-Chair: |
J. Thornton, UK
C.J. Thaler, Germany
J. Shalev, Israel |
| Capsule: |
Late abortion is mainly due to anatomical and
mechanical problems |
| |
- Second trimester miscarriage and delivery of a viable child
-
a controverse combination in delayed interval delivery
B. Arabin, The Netherlands
- Cervical Length And Funneling - The False Positive And False
Negative Observations
B. Arabin, The Netherlands
- The role for emergency cerclage –The role of the ultrasound
I. Timor-Tritsch, USA
- Can regular exercise affect fetoplacental growth?
J. Clapp, USA
|
| 10:30-12:15 |
PRENATAL SCREENING AND DIAGNOSIS |
| Co-Chair: |
C. Sohn, Germany
I.E. Timor-Tritsch, USA
S. Thornton, UK |
| Capsule: |
There is still no agreed policy on how to best
screen for anomalies |
| |
- Prenatal screening is best done in the first trimester
I. Timor-Tritsch, USA
- Does 3D Ultrasound contribute significantly to anomaly detection?
A. Kurjak, Croatia
- Controversies over N.T. testing
M. Bronstein, Israel
- The ethical issues of first trimester screening
J. Thornton, UK
- Does outlets views detect more cardiac anomalies then 4 chambers
view
M. Bronstein, Israel
|
| 15:15– 16:45 |
THROMBOPHILIA IN OBSTETRICS AND GYNAECOLOGY
Industrial Session by Aventis |
| Co-Chair: |
L.P. Shulman, USA
D. Blickstein, Israel |
| Capsule: |
Screening for Thrombophilia may be useful in preventing
complications |
| 15:15 |
Thrombophilia 2003 - overview
R. Zotz, Germany
|
| 15:39 |
What is the evidence for the relation
of thrombophilia to adverse pregnancy outcome?
B. Brenner, Israel |
| 16:03 |
Genetic thrombophilias and contraception
L.P. Shulman, USA |
| 16:27 |
The value of LMWH treatment in Ob/Gyn?
D. Blickstein, Israel |
| 16:45– 18:45 |
INTRAUTERINE GROWTH RESTRICTION |
| Co-Chair: |
J.O. Gardosi, UK
I.E. Timor-Tritsch, USA |
Capsule:
|
What are the most appropriate strategies for preventing
complications due to growth problems? |
| |
- Epidemiology and perinatal sequelae
J.O. Gardosi, UK
- IUGR and hypoxic-ischemic encephalopathy
R. Bukowski, USA
- Ultrasound biometry and fetal weight assessment
M. Mongelli, Singapore
- Fetal Genetic Problems associated with IUGR
L.P. Shulman, USA
- Open forum discussion
|
